Advertisement
AZTA vs MTD
Which Stock Would AI Choose? Azenta, Inc. (AZTA) vs. Mettler-Toledo International Inc. (MTD) Stock Comparison
Key Takeaways
- AZTA trades at a significant discount with a forward P/E (price-to-earnings ratio) of 29.07 compared to MTD's 27.03, but shows negative profit margins of -10.12% versus MTD's robust 21.59%.
- Recent market activity has pressured AZTA shares, with sharp declines amid operational challenges, while MTD maintains stability ahead of Q1 earnings.
- MTD boasts a larger market cap of $26.9 billion and consistent revenue growth of 3.98% year-over-year, contrasting AZTA's smaller $1.12 billion cap and 0.80% quarterly growth.
- Both stocks operate in life sciences and precision instruments, but MTD's diversified segments drive superior profitability and lower relative volatility (beta 1.31 vs. AZTA's 1.43).
- Analyst targets suggest upside for AZTA at $35.40 (90% potential), while MTD averages $1,488 (12% potential from current levels).
- Tickeron's AI tools highlight momentum in related sectors, aiding stock comparison analysis.
Introduction
This stock comparison examines AZTA and MTD, two players in the precision instruments and life sciences sectors serving pharmaceuticals, biotech, and research labs. Investors tracking healthcare equipment and analytical tools may find value in contrasting their business models, recent momentum, and market positioning. Amid broader market volatility and sector-specific demands like drug development and sample management, understanding relative performance helps evaluate growth potential, risk profiles, and sentiment shifts. This analysis draws on verifiable data to highlight key differences for informed decision-making in stock comparison strategies.
AZTA Overview and Recent Performance
Azenta, Inc. (AZTA) specializes in biological and chemical sample management solutions, including automated storage, cryogenic systems, and multiomics services like gene sequencing through its Sample Management Solutions and Multiomics segments. Headquartered in Burlington, Massachusetts, the company supports life sciences R&D globally.
In recent market activity, AZTA shares have faced volatility, trading around $18.66 with a market cap of $1.12 billion. Year-to-date returns stand at 43.91%, but one-year figures lag at 26.61% amid operational challenges and uneven execution. Recent weeks saw sharp declines, influenced by Q2 fiscal 2026 results that prompted updated guidance and analyst price target cuts, such as Evercore ISI lowering to $35 from $45 while maintaining Outperform. Sentiment reflects concerns over profitability (negative 10.12% margins) and slower growth, though leadership transitions aim to accelerate gene synthesis strategies.
MTD Overview and Recent Performance
Mettler-Toledo International Inc. (MTD) manufactures precision instruments including laboratory balances, pipetting solutions, industrial scales, and analytical tools across U.S., Swiss, Western European, Chinese, and other operations. Based in Greifensee, Switzerland, it caters to pharma, food, chemicals, and logistics with software like LabX for data management.
Recent performance for MTD shows resilience, with shares near $1,328 and a $26.9 billion market cap. YTD return is 4.75%, with 24.88% over one year. Stability persists ahead of Q1 2026 earnings, expected at $8.70 EPS (up 6.2%) and $946.75 million revenue (up 7.1%). Factors include quarterly revenue growth of 8.10% and strong profitability (21.59% margins), though growth has moderated to 3.98% year-over-year. Analyst sentiment remains positive, with targets averaging $1,488 and Barclays maintaining Overweight.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of top-performing AI trading bots from its library of over 351 bots that trade thousands of tickers across diverse strategies, timeframes, and sectors. AI analyzes all bots to spotlight the 25 most promising for current conditions, such as volatility plays in semiconductors, industrials, and leveraged ETFs. Standout stats include annualized returns up to +169%, win rates of 51-88%, and profit factors reaching 11.70—often outperforming the S&P 500. These virtual agents deploy real-time signals with risk management like TP/SL corridors, suiting momentum, sector rotation, and high-growth plays. Traders can explore copy trading options without minimum balances to leverage these tools in dynamic markets.
Head-to-Head Comparison
AZTA and MTD both target life sciences but diverge in scale and diversification: AZTA focuses narrowly on sample storage and multiomics (revenue $595M TTM), while MTD spans lab/industrial/retail instruments ($4.03B TTM) across geographies.
Growth drivers contrast: AZTA's 0.80% quarterly revenue growth lags MTD's 8.10%, with MTD benefiting from steady EPS expansion (13.30% quarterly). Recent momentum favors MTD's stability versus AZTA's post-earnings drops.
Risk factors include AZTA's higher beta (1.43) and debt/equity of 3.18%, offset by strong liquidity (current ratio 2.92); MTD offers lower beta (1.31) but premium valuation (P/S 6.47 vs. 1.88). Sector exposure ties both to biotech/pharma, but MTD's industrial/retail buffers sentiment shifts. Trade-offs: AZTA for value/upside potential, MTD for proven resilience.
Tickeron AI Verdict
Tickeron’s AI would currently favor MTD based on superior trend consistency, profitability (ROIC 46.90%), and catalysts like upcoming earnings with raised EPS estimates. While AZTA shows value via analyst targets and YTD gains, its volatility and negative margins suggest higher risk. Probabilistic edge tilts to MTD for relative stability in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTA is a StrongBuy and MTD is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 0 FA rating(s) are green whileMTD’s FA Score has 1 green FA rating(s).
- AZTA’s FA Score: 0 green, 5 red.
- MTD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 4 bullish TA indicator(s).
- AZTA’s TA Score: 4 bullish, 6 bearish.
- MTD’s TA Score: 4 bullish, 6 bearish.
Price Growth
AZTA (@Pharmaceuticals: Other) experienced а -0.44% price change this week, while MTD (@Medical Specialties) price change was -1.98% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.49%. For the same industry, the average monthly price growth was +1.13%, and the average quarterly price growth was -15.35%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
AZTA is expected to report earnings on Aug 11, 2026.
MTD is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| AZTA | MTD | AZTA / MTD | |
| Capitalization | 1.04B | 22.9B | 5% |
| EBITDA | 36.6M | 1.25B | 3% |
| Gain YTD | -32.081 | -18.842 | 170% |
| P/E Ratio | 42.43 | 26.58 | 160% |
| Revenue | 596M | 4.09B | 15% |
| Total Cash | 381M | 60.6M | 629% |
| Total Debt | 55.7M | 2.23B | 2% |
AZTA | MTD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 2 | |
PRICE GROWTH RATING 1..100 | 50 | 57 | |
P/E GROWTH RATING 1..100 | 87 | 60 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZTA's Valuation (52) in the Electronic Production Equipment industry is somewhat better than the same rating for MTD (99) in the Medical Specialties industry. This means that AZTA’s stock grew somewhat faster than MTD’s over the last 12 months.
AZTA's Profit vs Risk Rating (100) in the Electronic Production Equipment industry is in the same range as MTD (100) in the Medical Specialties industry. This means that AZTA’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is significantly better than the same rating for AZTA (95) in the Electronic Production Equipment industry. This means that MTD’s stock grew significantly faster than AZTA’s over the last 12 months.
AZTA's Price Growth Rating (50) in the Electronic Production Equipment industry is in the same range as MTD (57) in the Medical Specialties industry. This means that AZTA’s stock grew similarly to MTD’s over the last 12 months.
MTD's P/E Growth Rating (60) in the Medical Specialties industry is in the same range as AZTA (87) in the Electronic Production Equipment industry. This means that MTD’s stock grew similarly to AZTA’s over the last 12 months.
| AZTA | MTD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 59% |
| Advances ODDS (%) | 2 days ago 70% | 13 days ago 61% |
| Declines ODDS (%) | 9 days ago 82% | 6 days ago 65% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 56% |
Advertisement
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with XRAY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | +0.58% | ||
| XRAY - AZTA | 63% Loosely correlated | -0.49% | ||
| IQV - AZTA | 60% Loosely correlated | +0.22% | ||
| RVTY - AZTA | 59% Loosely correlated | -1.83% | ||
| A - AZTA | 59% Loosely correlated | +0.22% | ||
| MTD - AZTA | 59% Loosely correlated | -0.86% | ||
More | ||||
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | -0.86% | ||
| A - MTD | 71% Closely correlated | +0.22% | ||
| TMO - MTD | 67% Closely correlated | -1.33% | ||
| BRKR - MTD | 67% Closely correlated | -1.72% | ||
| DHR - MTD | 63% Loosely correlated | -0.38% | ||
| AZTA - MTD | 61% Loosely correlated | +0.58% | ||
More | ||||